Podcast: Student Innovation Holds Promise for Breast Cancer Screening
Imagine a faster, inexpensive method for breast cancer screening. That’s some of the promise behind a new innovation from doctoral student, Sevan Goenezen, who has discovered a way to use ultrasound and advanced algorithms to differentiate between benign and malignant tumors.
[[{"type":"media","view_mode":"media_crop","fid":"1735","attributes":{"alt":"","class":"media-image","id":"media_crop_7567161365917","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"201","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":" ","typeof":"foaf:Image"}}]]Imagine a fast, inexpensive method for breast cancer screening. That’s some of the promise behind a new innovation from a doctoral student who has discovered a way to use ultrasound and advanced algorithms to differentiate between benign and malignant tumors.
Sevan Goenezen, a student at the department of mechanical, aerospace, and nuclear engineering at Rensselaer Polytechnic Institute, researched nonlinear elasticity imaging for breast cancer diagnosis. Here Geonezen and his faculty advisor, Assad Oberai, discuss this innovation and what it could mean for breast cancer diagnosis, as well as diagnosis of other diseases.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
